An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases

BJU International

Volumn 95, Issue 6, 2005, Pages 743-749

  Evans, Christopher P ^a,e   Fleshner, Neil ^b   Fitzpatrick, John M ^c   Zlotta, Alexander R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Benign prostatic hyperplasia; Class effect; Evidence based medicine; Prostate cancer

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MEGESTROL ACETATE; NILUTAMIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TRIPTORELIN;

ALCOHOL INTOLERANCE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEMATURIA; HUMAN; MALE; MASTALGIA; META ANALYSIS; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATECTOMY; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINE FLOW RATE; VISUAL DISORDER;

ADRENERGIC ALPHA-ANTAGONISTS; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHOLESTENONE 5 ALPHA-REDUCTASE; EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 17444399653     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05390.x     Document Type: Conference Paper

References (40)

1. Sackett DL, Rosenberg WMC, Muir Gray JA, Haynes RB, Scott Richardson Y. Evidence based medicine, what it is and what it isn't. BMJ 1996; 312: 71-2
2. Evans CP. Evidence-based medicine for the urologist. BJU Int 2004; 94: 1-2
3. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature. XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999; 282: 1371-7
4. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer, a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77
5. Bandolier Professional. On quality and validity. Available at http://www.msdforphysicians.co.uk/bandolier/qvs.pdf 2003 Accessed 2 March 2004
6. McNeill SA, Hargreave TB, Geffriaud-Ricouard C, Santoni J, Roehrborn CG. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology 2001; 57: 459-65
7. Wilt TJ, Howe W, MacDonald R. Terazosin for treating symptomatic benign prostatic obstruction, a systematic review of efficacy and adverse effects. BJU Int 2002; 89: 214-25
8. Wilt TJ, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction, a systematic review of efficacy and adverse effects. J Urol 2002; 167: 177-83
9. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13
10. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91: 41-4
11. Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. Int J Urol 2000; 7: 199-205
12. Okada H, Kamidono S, Yoshioka T et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 2000; 85: 676-81
13. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2002; 2: 1-17
14. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
15. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
16. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003; 92: 226-31
17. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K, on behalf of Study Group. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-8
18. Vogelzang NJ, Chodak GW, Soloway MS et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995; 46: 220-6
19. de Voogt HJ, Studer U, Schroder FH, Klijn JG, De Pauw M, Sylvester R. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1998; 33: 152-8
20. Bruun E, Frimodt-Moller C, The effect of buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The 'Danish Buserelin Study Group'. Scand J Urol Nephrol 1996; 30: 291-7
21. Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987; 59: 248-54
22. Huben RP, Murphy GP. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 1988; 62: 1881-7
23. Klioze SS, Miller MF, Spiro TP. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Am J Clin Oncol 1988; 11 (Suppl. 2): S176-S182
24. Osborne DR, Moffat LEF, Kaisary A, Rees DLP, Weaver JP. A comparison of Zoladex, cyproterone acetate and stilboestrol in the treatment of patients with advanced prostatic cancer. Recent Advances in Urological Cancers Diagnosis and Treatment. Paris June 27-29 1990: 53-5
25. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-6
26. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ. A prospective, randomised study to compare goserelin acetate (Zoladex®) versus cyproterone acetate (Cyprostat®) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47-54
27. Waymont B, Lynch TH, Dunn JA et al. Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992; 69: 614-20
28. Bandolier. LHRH analogues in prostate cancer. An overview of randomised trials, with perspectives on possible meta-analysis. Available at www.ebandolier.com 2003 Accessed 26 January 2004
29. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-8
30. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7
31. Bolla M, de Reijke ThM, Zurlo A, Collette L. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials. Front Radiat Ther Oncol 2002; 36: 81-6
32. Pilepich MV, Winter K, Lawton C et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol 2003; 22: 381, A1530
33. Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-8
34. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
35. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003; 169: 396, A1480
36. Pilepich MV, Winter K, John MJ et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52
37. Roach M III, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11
38. Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000; 164: 1465-72
39. Schellhammer PF, Sharifi R, Block NL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997; 50: 330-6
40. Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. Urooncology 2004; 4: 5-13